A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers

por Halperin, Daniel M, Phan, Alexandria T, Hoff, Ana O, Aaron, Marie, Yao, James C, Hoff, Paulo M
Publicado 2014

Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis

por Mehrvarz Sarshekeh, Amir, Advani, Shailesh, Halperin, Daniel M., Conrad, Claudius, Shen, Chan, Yao, James C., Dasari, Arvind
Publicado 2017

Population-Based Study of Islet Cell Carcinoma

por Yao, James C., Eisner, Milton P., Leary, Colleen, Dagohoy, Cecile, Phan, Alexandria, Rashid, Asif, Hassan, Manal, Evans, Douglas B.
Publicado 2007

Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors

por Pudakalakatti, Shivanand, Titus, Mark, Enriquez, José S., Ramachandran, Sumankalai, Zacharias, Niki M., Shureiqi, Imad, Liu, Yi, Yao, James C., Zuo, Xiangsheng, Bhattacharya, Pratip K.
Publicado 2022

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial

por Lombard-Bohas, Catherine, Yao, James C., Hobday, Timothy, Van Cutsem, Eric, Wolin, Edward M., Panneerselvam, Ashok, Stergiopoulos, Sotirios, Shah, Manisha H., Capdevila, Jaume, Pommier, Rodney
Publicado 2015

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

por Yao, James C, Chan, Jennifer A, Mita, Alain C, Kundu, Madan G, Hermosillo Reséndiz, Karina, Hu, Ke, Ravichandran, Shoba, Strosberg, Jonathan R, Wolin, Edward M
Publicado 2017

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis

por Strosberg, Jonathan R, Yao, James C, Bajetta, Emilio, Aout, Mounir, Bakker, Bert, Hainsworth, John D, Ruszniewski, Philippe B, Van Cutsem, Eric, Öberg, Kjell, Pavel, Marianne E
Publicado 2015

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

por Yao, James C, Oh, Do-Youn, Qian, Jiaming, Park, Young Suk, Herbst, Fabian, Ridolfi, Antonia, Izquierdo, Miguel, Ito, Tetsuhide, Jia, Liqun, Komoto, Izumi, Sriuranpong, Virote, Shimada, Yasuhiro
Publicado 2019

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4

por Buzzoni, Roberto, Carnaghi, Carlo, Strosberg, Jonathan, Fazio, Nicola, Singh, Simron, Herbst, Fabian, Ridolfi, Antonia, Pavel, Marianne E, Wolin, Edward M, Valle, Juan W, Oh, Do-Youn, Yao, James C, Pommier, Rodney
Publicado 2017

PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment

por Liu, Yi, Wei, Daoyan, Deguchi, Yasunori, Xu, Weiguo, Tian, Rui, Liu, Fuyao, Xu, Min, Mao, Fei, Li, Donghui, Chen, Weidong, Valentin, Lovie Ann, Deguchi, Eriko, Yao, James C., Shureiqi, Imad, Zuo, Xiangsheng
Publicado 2023

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

por Mahvash, Armeen, Murthy, Ravi, Odisio, Bruno C, Raghav, Kanwal Pratap, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Ensor, Joe, Gadani, Sameer, Elsayes, Khaled M, Abdel-Wahab, Reham, Hassan, Manal, Shalaby, Ahmed S, Yao, James C, Wallace, Michael J, Kaseb, Ahmed O
Publicado 2016

Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma

por Kaseb, Ahmed O., Haque, Abedul, Vishwamitra, Deeksha, Hassan, Manal M., Xiao, Lianchun, George, Bhawana, Sahu, Vishal, Mohamed, Yehia I., Carmagnani Pestana, Roberto, Lombardo, Jamie Lynne, Avritscher, Rony, Yao, James C., Wolff, Robert A., Rashid, Asif, Morris, Jeffrey S., Amin, Hesham M.
Publicado 2022

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

por Kaseb, Ahmed O, Morris, Jeffrey S, Iwasaki, Michiko, Al-Shamsi, Humaid O, Raghav, Kanwal Pratap Singh, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Elsayes, Khaled M, Xiao, Lianchun, Abdel-Wahab, Reham, Shalaby, Ahmed S, Hassan, Manal, Hassabo, Hesham M, Wolff, Robert A, Yao, James C
Publicado 2016

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

por Fazio, Nicola, Buzzoni, Roberto, Delle Fave, Gianfranco, Tesselaar, Margot E., Wolin, Edward, Van Cutsem, Eric, Tomassetti, Paola, Strosberg, Jonathan, Voi, Maurizio, Bubuteishvili‐Pacaud, Lida, Ridolfi, Antonia, Herbst, Fabian, Tomasek, Jiri, Singh, Simron, Pavel, Marianne, Kulke, Matthew H., Valle, Juan W., Yao, James C.
Publicado 2017

Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ

por Liu, Yi, Deguchi, Yasunori, Wei, Daoyan, Liu, Fuyao, Moussalli, Micheline J., Deguchi, Eriko, Li, Donghui, Wang, Huamin, Valentin, Lovie Ann, Colby, Jennifer K., Wang, Jing, Zheng, Xiaofeng, Ying, Haoqiang, Gagea, Mihai, Ji, Baoan, Shi, Jiaqi, Yao, James C., Zuo, Xiangsheng, Shureiqi, Imad
Publicado 2022

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma

por Chamseddine, Shadi, Mohamed, Yehia I., Lee, Sunyoung S., Yao, James C., Hu, Zishuo Ian, Tran Cao, Hop S., Xiao, Lianchun, Sun, Ryan, Morris, Jeffrey S., Hatia, Rikita I., Hassan, Manal, Duda, Dan G., Diab, Maria, Mohamed, Amr, Nassar, Ahmed, Datar, Saumil, Amin, Hesham M., Kaseb, Ahmed Omar
Publicado 2023

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors

por Salazar, Ramon, Garcia‐Carbonero, Rocio, Libutti, Steven K., Hendifar, Andrew E., Custodio, Ana, Guimbaud, Rosine, Lombard‐Bohas, Catherine, Ricci, Sergio, Klümpen, Heinz‐Josef, Capdevila, Jaume, Reed, Nicholas, Walenkamp, Annemiek, Grande, Enrique, Safina, Sufiya, Meyer, Tim, Kong, Oliver, Salomon, Herve, Tavorath, Ranjana, Yao, James C.
Publicado 2017

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma

por Kaseb, Ahmed Omar, Kappadath, S Cheenu, Lee, Sunyoung S, Raghav, Kanwal Pratap, Mohamed, Yehia I, Xiao, Lianchun, Morris, Jeffrey S, Ohaji, Chimela, Avritscher, Rony, Odisio, Bruno C, Kuban, Joshua, Abdelsalam, Mohamed E, Chasen, Beth, Elsayes, Khaled M, Elbanan, Mohamed, Wolff, Robert A, Yao, James C, Mahvash, Armeen
Publicado 2021

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

por Mohamed, Yehia I., Duda, Dan G., Awiwi, Muhammad O., Lee, Sunyoung S., Altameemi, Lina, Xiao, Lianchun, Morris, Jeffrey S., Wolff, Robert A., Elsayes, Khaled M., Hatia, Rikita I., Qayyum, Aliya, Chamseddine, Shadi M., Rashid, Asif, Yao, James C., Mahvash, Armeen, Hassan, Manal M., Amin, Hesham M., Kaseb, Ahmed Omar
Publicado 2022